Context: Recent studies using skin biopsy suggest presence of small-fiber neuropathy in subclinical hypothyroidism. This study uses two noninvasive methods-the laser Doppler imager flare technique (LDI FLARE ) and corneal confocal microscopy (CCM)-to assess small-fiber function (SFF) and small-fiber structure (SFS), respectively, in newly diagnosed hypothyroidism (HT) before and after adequate treatment.
T he presence of neuromuscular dysfunction in hypothyroidism (HT) is well recognized, with a prevalence ranging between 42% and 72% (1, 2) . Epidemiological neurologic studies have reported HT as a cause in 2% to 5% of cases of polyneuropathy (3) (4) (5) . Peripheral neuropathy, such as diffuse sensorimotor neuropathy involving myelinated large nerve fibers like Aa and Ab, have been commonly described; symptoms are usually mild and predominantly sensory (6) . Beghi et al. (1) studied 39 consecutive patients with hypothyroidism and detected sensory symptoms in 64%, of whom 72% had neurophysiological evidence and only 33% had clinical signs. Similarly, in another case series comprising of 24 patients with newly diagnosed HT, Duyff et al. (7) reported clinical signs of predominantly sensory peripheral neuropathy in only 42% of patients. Clinical signs in HT are usually subtle and nonspecific, with reduced knee and ankle reflexes along with mild impairment of distal vibration and joint position sense (6) . The pathological changes described include axonal degeneration, segmental demyelination, and deposition of mucopolysaccharides in the endoneurial interstitium (2, 8, 9) . Such changes have been described to be more related to the duration of HT than to the severity of thyroid failure (10) .
In many neuropathies, including diabetes and chemotherapy-induced peripheral neuropathy, smallfiber neural involvement affecting the thinly myelinated Ad and nonmyelinated C fibers has been shown to precede largefiber involvement (11, 12) . However, in HT, limited evidence suggests early small-fiber neural involvement, especially in asymptomatic individuals. In a series of 38 hypothyroid patients, Ørstavik et al. (13) demonstrated significantly abnormal thermal thresholds as compared with controls. In a smaller study of 18 neurologically asymptomatic patients with newly diagnosed overt or subclinical HT, Magri et al. (14) found significantly reduced intraepidermal nerve fiber density (IENFD) in their distal leg skin biopsy specimens but no evidence of large-fiber dysfunction assessed by conventional neurophysiological tests. Subsequently, the same authors showed that such impairment of IENFD was reversible after levothyroxine (LT 4 ) treatment in nine patients (15) . With the exception of these studies, we are unaware of any other studies specifically assessing other modalities of small-fiber involvement in patients with HT. In this prospective study, we used two noninvasive methods -the laser Doppler imager flare technique (LDI FLARE ) and corneal confocal microscopy (CCM) -to assess small-fiber function (SFF) and structure (SFS), respectively, in patients with newly diagnosed HT compared with a cohort of age-and sex-matched healthy controls (HCs), as well as the change before and after adequate monotherapy with LT 4. Neither SFF nor SFS has been studied together in HT, and hence this study can be considered as a proof-of-concept study investigating early neuropathic changes in HT.
Patients and Methods

Ethical approval
This study was conducted between 2014 and 2017 in accordance with the Declaration of Helsinki and was approved by the ethics committee of the National Research Ethics Service Committee East of England, Norfolk, United Kingdom (Research Ethics Committee reference: 13/EE/0162). All participants provided written informed consent.
Study design and participant selection
Twenty patients with newly diagnosed HT along with 20 age-and sex-matched HCs were recruited, the latter by invitation from the local population. HT was diagnosed by a TSH level of $10 IU/mL with an abnormally low free T 4 (FT 4 ) level (see below). Of the 20 patients with HT, 15 had primary HT (PyHT) and 5 had radioiodine-induced HT (RiHT) occurring at least 6 weeks after administration of radioiodine treatment. We included both types of HT to determine whether the neurologic profile would differ given the difference in cause and duration of the HT. None of the patients with RiHT had any neurologic symptoms before administration of radioiodine.
Patients who had a history of HT and were receiving thyroid supplementation at any stage in their life were excluded because we also aimed to look at the effects of LT 4 supplementation on neurologic parameters. Patients with a history of impaired fasting glycemia, prediabetes, or diabetes (type 1, type 2, or other specific types) as per the 2018 diagnostic criteria of the American Diabetes Association (16) were excluded on the basis of a fasting blood glucose and glycosylated hemoglobin A 1c . Patients were also excluded if they had any history of peripheral arterial disease, hypertriglyceridemia, alcohol abuse, vitamin B12 and folate deficiency, thyroid or connective tissue disorders, renal or hepatic failure, malignancy, inherited neuropathy, or exposure to any toxins (including chemotherapy).
Clinical and biochemical assessment
All participants underwent baseline biochemical assessment for thyroid fasting glucose, glycosylated hemoglobin A 1c , lipids, renal and hepatic profiles, vitamin B12, and folate. Thyroid biochemistry comprised TSH, FT 4 , and antithyroid peroxidase antibodies (anti-TPOab). Serum concentrations of TSH (noncompetitive sandwich immunoassay; normal range, 0.27 to 4.20 mIU/L) and FT 4 (competitive immunoassay; normal range, 12 to 22 pmol/L), and anti-TPOab (normal range, 0 to 34 U/mL) were measured with electrochemiluminescent detection using an automated analyzer (Cobas e602 immunochemical analyzer) employing commercial kits (Roche Diagnostics Ltd, Bugess Hill, UK). The TSH assay has a functional sensitivity of 0.014 mIU/L and limit of detection of 0.005 mIU/L, with interassay coefficients of variation (CVs) of 2.1% and 2.0% at concentrations of 1.2 mIU/L and 7.9 mIU/L, respectively. The FT 4 assay has a functional sensitivity of 3.0 pmol/L and limit of detection of 0.5 pmol/L, with interassay CVs of 2.1% and 2.8% at concentrations of 15.4 pmol/L and 39.8 pmol/L, respectively. The anti-TPOab assay has an interassay CV of 8% at 34 U/mL and 5% at 92 U/mL, the limit of detection is 5 U/mL, and the measuring range is 5 to 600 U/mL.
A total of 32 patients with HT were initially screened, of whom 8 were excluded because of a new diagnosis of prediabetes, diabetes, or vitamin B12 deficiency. A further four patients were lost during follow-up because of a diagnosis of diabetes (two patients), cancer (one patient), and stroke (one patient). All participants, including HCs, completed the Thyroid Symptom Questionnaire (TSQ)-a 12-point questionnaire validated for use in hypothyroidism (17)-at the beginning and end of the study. Both groups also underwent detailed neurologic examination with the modified Neuropathy Disability Score (18) . SFF was assessed with LDI FLARE and SFS was measured by CCM. Vibration perception threshold was measured on the toes by using the Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK) and expressed as millivolts (mV). Sural nerve conduction velocity (SNCV) and sural nerve amplitude (SNAP) were assessed in one leg (NC-stat|DPNCheck system; Neurometrix, Waltham, MA). The neurologic assessments were repeated for both groups at the end of the study.
LDI FLARE method
SFF was assessed by using the noninvasive LDI FLARE technique as previously published (19) . In a thermally controlled room at 30°C, the dorsal foot skin is heated sequentially to 44°C for 2 minutes, 46°C for 1 minute, and finally to 47°C for 3 minutes using a 1-cm 2 heating probe. This nociceptive heat results in activation of the C-fiber reflex and the resultant nerveaxon-related hyperemic response is assessed by using a laser scanner (Moor Instruments, Axminster, UK). The size of the hyperemic response is measured in centimeters squared (cm 2 ) by using the Moor V 5.3 software, referred to as the LDI FLARE ( Fig. 1 ). Flare size relates to SFF; a small flare equates to reduced SFF. The time needed for this assessment is up to 30 minutes. Previous studies have demonstrated that it is a sensitive method to detect C-fiber dysfunction as an early marker of small-fiber neuropathy (SFN) in both type 2 diabetes (20) and impaired glucose tolerance (21) . It has significant correlations with IEFND (22) and recently has been shown to be more sensitive than neurophysiological studies to detect SFF in early chemotherapy-induced peripheral neuropathy (12) .
CCM method
Small-fiber structure was measured by CCM using the laser scanning Retina Tomograph III confocal microscope with Rostock Corneal Module (Heidelberg Engineering GmbH, Dossenheim, Germany) by following an established technique. The total duration of examination of both eyes was 5 to 10 minutes (23, 24) . Before scanning, topical anesthesia [oxybuprocaine hydrochloride 0.4% (Minims ® ); Bausch & Lomb, Kingston upon Thames, Surrey, UK] was applied to the cornea of both eyes, followed by topical application of a viscous gel [carbomer 980 polyacrylic acid 0.2% (Viscotears ® ); Alcon Eye Care, Frimley, Surrey, UK] to form an aqueous medium between the applanated corneal surface and disposable TomoCap (Heidelberg Engineering Ltd., Hemel Hempstead, UK) covering the objective lens. Several scans of the entire depth of the cornea of both eyes were taken by fine adjustment of the objective lens, resulting in manual acquisition of two-dimensional images with a final image size of 400 3 400 pixels and lateral resolution of 2 mm/pixel of the subbasal nerve plexus of the cornea. Each subbasal nerve fiber bundle contains unmyelinated neural fibers running parallel to the Bowman layer before terminating dividing and terminating as individual axons just underneath the corneal surface epithelium. The six best images from the center of the cornea were manually selected for automated image analysis by using purpose-written, proprietary software (CCM Image Analysis tool v1.1; Imaging Science and Biomedical Engineering, University of Manchester, Manchester, UK) (25) . The specific parameters measured per frame were as follows: CCM nerve fiber damage (CNFD; number of fibers/mm 
Management of HT
All patients with HT were treated with LT 4 monotherapy as per 2014 guidelines suggested by the American Thyroid Association (26) . The dosage of LT 4 was titrated to achieve the TSH reference range of 0.27 to 4.20 mIU/L at 12-weekly intervals. Once a stable TSH was achieved for at least 6 months, the patients with HT thereafter completed the TSQ questionnaire and all the neurologic assessments previously undertaken. 
Statistical analysis
Statistical analysis was performed by using SPSS software, version 20 for Windows (IBM, Armonk, NY) and StatsDirect software, version 3 (StatsDirect Ltd, Cambridge, UK). Analysis included descriptive and frequency statistics. All data are expressed as mean 6 SD. Normal distribution of the data was determined with the Kolmogorov-Smirnov test. An independentsample t test was used to test whether a sample mean differed between the HT and HC groups. A paired sample t test was used to for the comparison between baseline and follow-up data. Nonparametric data were analyzed by using the x 2 test. Pearson bivariate correlation was used to see the relationship between baseline TSH and neurologic assessments. Power was calculated by using the Wilks lambda model and computed by using a = 0.05. Statistical significance was defined at 5% (i.e., P # 0.05). The CVs for CCM and LDI FLARE are 7.8% and 8.7%, respectively. Table 1 shows the clinical characteristics and biochemical assessments of all 20 newly diagnosed patients with HT who were enrolled and completed follow-up in the study. In all 15 patients with PyHT, that condition was due to autoimmune thyroiditis characterized by raised anti-TPOab levels (.34 IU/mL). The remaining five patients had RiHT that developed after radioiodine treatment of Graves thyrotoxicosis (three of five patients) and solitary toxic nodule (two of five patients). None of the patients were receiving any form of thyroid replacement therapy, including LT 4 , at study entry. Table 2 shows the clinical characteristics of and comparisons between the HT and HC groups at baseline and at the end of the study period. Both groups were matched for age, sex, and body mass index (P $ 0.05). Systolic blood pressure was modestly higher in the HT group (P = 0.04) but lipid profiles did not differ (P $ 0.05). As expected, the TSH, FT 4 , anti-TPOab titers, and TSQ score were significantly abnormal in the HT group (P # 0.0001). Both measures of SFN-LDI FLARE (P # 0.0001) and CCM (P # 0.002 for all three parameters)-were significantly lower in patients with HT than in HCs (Fig. 1) . None of the three measures of large-fiber neuropathy-SNCV, SNAP, and vibration perception threshold (VPT)-differed between the groups (P = .0.05).
Results
Differences in baseline characteristics
Baseline correlates of TSH with small-and large-fiber indices
The baseline TSH of all study participants was compared with the initial small-and large-fiber neural indices. Figure 3 demonstrates a significant inverse correlation between baseline TSH and LDI FLARE (r = 20.719; P # 0.0001), CNFD (r = 20.492; P = 0.008), and CNFL (r = 20.382; P = 0.01) but not with CNBD (r = 0.044; P = 0.41). In comparison, none of the large-fiber parameters-SNCV (P = 0.09), SNAP (P = 0.06), and VPT (P = 0.11)-showed any significant correlation with baseline TSH. In HCs, neither smallnor large-fiber parameters demonstrated any significant correlations (P $ 0.05) with baseline TSH. There was also a significant correlation between baseline TSH and TSQ scores (r = 0.70; P = 0.008). Comparison of FT 4 levels with both large-and small-fiber neurologic parameters revealed no significant correlation (P $ 0.05).
After the initial assessment, all patients with HT began receiving LT 4 monotherapy, with doses titrated per 2014 guidelines suggested by the American Thyroid Association (26) . After the target TSH was achieved and remained stable for $6 months, the patients with HT were reassessed again for neurophysiological changes.
Differences in characteristics at study end Table 2 and Fig. 4 none of the large-fiber modalities-SNCV (P = 0.21), SNAP (P = 0.26), and VPT (P = 0.53)-showed any significant change. The inverse correlations between TSH and small-fiber indices (LDI FLARE , CNFD, and CNFL) observed in the pretreatment period were not seen at the end of the study period (P $ 0.05) b At 1 y in HCs and after $6 months of stable LT 4 replacement in patients with HT.
As shown in Fig. 5 , all HCs were reassessed after 1 year and their results were compared with the final outcomes of the HT group. Despite achievement of stable and normal TSH levels in the latter, when compared with HCs, the small neural indices remained significantly lower. The LDI FLARE in the HC group, 8.81 6 0.99 cm 2 , remained significantly higher than the value in the HT group. 8.45 6 0.60 cm 2 (P = 0.02). A similar significant difference was observed with CNFD (56.67 6 6.12 vs 54.43 6 5.70 no./mm 2 ; P = 0.04) and CNBD (35.86 6 7.17 vs 32.81 6 7.91 no./mm 2 ; P = 0.02) but not with CNFL (13.71 6 3.563 vs 13.43 6 2.25 mm/mm 2 ; P = 0.05), respectively. None of the large-fiber parameters significantly differed between the HC and HT groups at the end of the study. Finally, no significant differences in baseline or follow-up outcomes were observed between the PyHT and RiHT groups at any level.
Discussion
Neuromuscular dysfunction is common in patients with HT and has been historically associated with sensorimotor polyneuropathy and other peripheral neuropathies (1, 27, 28) . Previous studies have inconsistently reported the prevalence of such polyneuropathy in hypothyroid patients to vary from 42% to 72% (1, 7) . However, these studies, using predominantly markers of large-fiber function, were in symptomatic patients with long-standing hypothyroidism with a wide distribution of neurologic involvement ranging from entrapment neuropathy to more diffuse peripheral neuropathy (29) . Such major neurologic sequelae are now rare because of earlier diagnosis and earlier replacement with LT 4 . However, in neurologically asymptomatic patients, there is conflicting evidence of polyneuropathy when largefiber function is assessed by measurement of nerve conduction; some studies suggest its presence (30) but others have not (13) . In this context, recent studies have demonstrated abnormalities in SFS in HT. In a group of 18 asymptomatic patients with subclinical or overt hypothyroid patients, Magri et al. (14) demonstrated significantly reduced IENFD in skin biopsy specimens from the upper thigh and distal leg, leading to the suggestion that "a considerable number of untreated hypothyroid patients may have preclinical asymptomatic small fibre neuropathy." However, although IENFD has traditionally been considered as the gold standard for investigating small-fiber neuropathy, its invasiveness may limit repetitive study; moreover, the technique still lacks a consensus reference standard (31) . Our proof-of-concept study compared large and small neural measures in 20 patients with untreated HT vs 20 age-and sex-matched HCs. All 15 patients with PyHT were referred to hospital services for management of newly diagnosed HT; however, on the basis of symptoms alone, it is not possible to know the duration of their Despite this, at baseline none of the large-fiber modalities (SNCV, SNAP, and VPT) had significantly abnormal results. In contrast, both small-fiber measures (LDI FLARE and CCM) were significantly reduced (P # 0.0001 and P = # 0.002, respectively) in comparison with values in HCs. This supports the hypothesis that SFN in untreated early HT precedes large-fiber neural involvement and adds to Magri and colleagues findings (14) that IEFND may be abnormal in hypothyroid patients in the presence of normal large-fiber function. Furthermore, in addition to demonstrating structural small-fiber deficits using a different but noninvasive method (CCM), our study for the first time demonstrates significant functional abnormality (LDI FLARE ) in patients with early HT.
We found that the baseline TSH had a significant inverse correlation with both LDI FLARE and CCM (P # 0.0001 and P # 0.01, respectively) but not with largefiber methods. Our findings contrast with the results of Magri et al. (14) , who did not find any significant correlation between TSH and IENFD. This disparity could be explained by the inclusion of patients with subclinical HT in the latter study; that would also explain the wide TSH range in comparison with the current study (77.19 6 92.80 mIU/L in the study by Magri et al. vs 83.47 6 31.18 mIU/L in the current study). Previous studies that used large-fiber methods hypothesized that severity of peripheral neuropathy in HT was related to duration of HT but not to the degree of thyroid failure (2, 10) . On the basis of our findings, we suggest that these more sensitive and recent methods of SFN assessment not only detect early neural involvement but also relate to severity of deficiency as indicated by serum TSH levels.
After establishment of a euthyroid state with LT 4 replacement therapy, both small-fiber indices significantly improved (LDI FLARE , P # 0.0001; CCM, P # 0.02), whereas large-fiber function did not change. We are aware of only one other prospective study, again by Magri et al. (15) , whose small study of nine patients with HT (six with overt and three with subclinical disease) demonstrated significant reversibility of previously reduced IENFD. The neural improvement detected by the methods used in our study underlines the sensitivity of these methods in contrast to measures of large-fiber function. In addition, unlike IENFD, these methods are noninvasive and thus have the advantage of being repeatable.
Of potential interest was the finding that despite normalization of TSH in all patients with HT, the smallfiber indices remained significantly reduced compared with those in the HCs: LDI FLARE (P = 0.02) and CCM (P # 0.05). This may suggest that a longer period of replacement therapy is necessary before small-fiber function and structure return to normal. Restoration of normal neural cellular function may also require the TSH to be in the lower half of the normal range; however, in this study we did not find a difference between patients with TSH levels in the lower quartile vs those with a normal reference range vs those in the upper quartile. A further study of similar design with more patients in whom a euthyroid state is maintained for a longer period would be necessary to determine whether this observation of persistent reduction of small-fiber neural indices is permanent.
This study is not without its limitations. Although these patients were newly diagnosed, they may have had long-standing hypothyroidism, which would explain the very high TSH in the group. It would be of interest to study patients with less biochemical severity, including subclinical hypothyroidism. It is important that our findings be confirmed by other studies, in particular because we studied only 20 patients; however, the high level of significance of the baseline findings and the improvements after treatment suggest that a type II error is unlikely.
Conclusion
This study demonstrates that small-fiber neuropathy precedes large-fiber dysfunction in early HT. This can be improved by achieving a biochemically euthyroid state with LT 4 replacement therapy, but even after 6 months of maintaining this euthyroid state, small-fiber neural indices continued to be remain low when compared with values in HCs.
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